BETA: Please send your feedback!
Five Prime Therapeutics
FPRX:NAS
Biotechnology
$143.45mm
SMALL cap
$3.90
(-0.19%)
-0.61%
since start of 2019
-0.87
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2001
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Marc L. Belsky, MBA, CPA | Chief Financial Officer & Senior Vice President | Male |
| Lewis T. Williams, MD, PhD | Chairman, President & Chief Executive Officer | Male |
| Heather Rowe | Director-Investor Relations & Communications | Female |
| Jeff P. Coon | Senior Vice President-Human Resources | Male |
| Aron M. Knickerbocker, MBA | Chief Operating Officer & Director | Male |
| Luis Borges, PhD | Senior Vice President-Research | Male |
| Helen Collins, MD | Chief Medical Officer & Senior Vice President | null |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
Five Prime Therapeutics - Competitors and Related Companies
How Five Prime Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Five Prime Therapeutics
FPRX:NAS
Biotechnology
$143.45mm
SMALL cap
$3.90
(-0.19%)
-0.61%
since start of 2019
-0.87
Regeneron Pharmaceuticals
REGN:NAS
Biotechnology
$33.40bn
LARGE cap
$303.93
(5.94%)
-0.18%
since start of 2019
15.93
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
$90.37bn
MEGA cap
$55.24
(2.04%)
0.05%
since start of 2019
14.49
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
$105.80bn
MEGA cap
$109.58
(1.68%)
-0.05%
since start of 2019
26.05
GlaxoSmithKline
GSK-GB:LON
Pharmaceuticals: Major
$105.77bn
MEGA cap
$42.74
(0.14%)
0.13%
since start of 2019
18.38
Pfizer
PFE:NYS
Pharmaceuticals: Major
$202.13bn
MEGA cap
$36.55
(0.09%)
-0.15%
since start of 2019
16.39